A
Akonni Biosystems
Molecular diagnostics developing and marketing integrated molecular diagnostic systems
About Akonni Biosystems
Akonni Biosystems operates in the molecular diagnostics market, focusing on the development and large-scale manufacturing of cost-effective genetic testing devices. The company specializes in addressing complex infectious diseases, such as multi-drug-resistant tuberculosis (MDR-TB). Utilizing a revolutionary gel-drop microarray platform, Akonni provides sophisticated yet affordable solutions for high-yield sample preparation and multiplex array imaging and analysis. The business model revolves around selling these diagnostic devices and associated instrumentation to healthcare providers, research institutions, and laboratories. Revenue is generated through the sale of these products, which are designed to offer high accuracy and efficiency in disease detection and management.
Source: Dealroom company dataAt a glance
- Founded
- 2003
- Headquarters
- Frederick, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A1 investor entered at this stage
Argonne National Laboratory
Series B and later2 investors entered at this stage
Maryland Venture Fund- MCM.M. Dillon & Co.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Akonni Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Akonni Biosystems on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.